Literature DB >> 34413116

Uptake and Predictors of Opportunistic Salpingectomy for Ovarian Cancer Risk Reduction in the United States.

Pritesh S Karia1,2, Corinne E Joshu1,3, Kala Visvanathan4,3.   

Abstract

Evidence suggesting that high-grade serous ovarian cancers originate in the fallopian tubes has led to the emergence of opportunistic salpingectomy (OS) as an approach to reduce ovarian-cancer risk. In the U.S., some national societies now recommend OS in place of tubal ligation for sterilization or during a benign hysterectomy in average-risk women. However, limited data exist on the dissemination of OS in clinical practice. We examined the uptake and predictors of OS in a nationwide sample of inpatient and outpatient claims (N = 48,231,235) from 2010 to 2017. Incidence rates of OS were calculated, and an interrupted time-series analysis was used to quantify changes in rates before (2010-2013) and after (2015-2017) national guideline release. Predictors of OS use were examined using Poisson regression. From 2010 to 2017, the age-adjusted incidence rate of OS for sterilization and OS during hysterectomy increased 17.8-fold [95% confidence interval (CI), 16.2-19.5] and 7.6-fold (95% CI, 5.5-10.4), respectively. The rapid increase (age-adjusted increase in quarterly rates of between 109% and 250%) coincided with the time of national guideline release. In multivariable-adjusted analyses, OS use was more common in young women and varied significantly by geographic region, rurality, family history/genetic susceptibility, surgical indication, inpatient/outpatient setting, and underlying comorbidities. Similar differences in OS uptake were noted in analyses limited to women with a family history/genetic susceptibility to breast/ovarian cancer. Our results highlight significant differences in OS uptake in both high- and average-risk women. Defining subsets of women who would benefit most from OS and identifying barriers to equitable OS uptake is needed. PREVENTION RELEVANCE: Opportunistic salpingectomy for ovarian-cancer risk reduction has been rapidly adopted in the U.S., with significant variation in uptake by demographic and clinical factors. Studies examining barriers to opportunistic salpingectomy access and the long-term effectiveness and potential adverse effects of opportunistic salpingectomy are needed. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34413116      PMCID: PMC8756422          DOI: 10.1158/1940-6207.CAPR-21-0121

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  30 in total

1.  Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial.

Authors:  Austin D Findley; Matthew T Siedhoff; Kumari A Hobbs; John F Steege; Erin T Carey; Christina A McCall; Anne Z Steiner
Journal:  Fertil Steril       Date:  2013-08-29       Impact factor: 7.329

2.  Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.

Authors:  Denise R Nebgen; Jean Hurteau; Laura L Holman; Andrea Bradford; Mark F Munsell; Beth R Soletsky; Charlotte C Sun; Gary B Chisholm; Karen H Lu
Journal:  Gynecol Oncol       Date:  2018-05-04       Impact factor: 5.482

3.  National trends of adnexal surgeries at the time of hysterectomy for benign indication, United States, 1998-2011.

Authors:  Emad Mikhail; Jason L Salemi; Mulubrhan F Mogos; Stuart Hart; Hamisu M Salihu; Anthony N Imudia
Journal:  Am J Obstet Gynecol       Date:  2015-04-30       Impact factor: 8.661

4.  Trends in Inpatient and Outpatient Hysterectomy and Oophorectomy Rates Among Commercially Insured Women in the United States, 2000-2014.

Authors:  Kemi M Doll; Stacie B Dusetzina; Whitney Robinson
Journal:  JAMA Surg       Date:  2016-09-01       Impact factor: 14.766

5.  Committee opinion no. 620: Salpingectomy for ovarian cancer prevention.

Authors: 
Journal:  Obstet Gynecol       Date:  2015-01       Impact factor: 7.661

6.  The impact of alternative treatment for abnormal uterine bleeding on hysterectomy rates in a tertiary referral center.

Authors:  Heleen van Dongen; Amy G van de Merwe; Cornelis D de Kroon; Frank Willem Jansen
Journal:  J Minim Invasive Gynecol       Date:  2008-11-05       Impact factor: 4.137

7.  Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.

Authors:  David C Grossman; Susan J Curry; Douglas K Owens; Michael J Barry; Karina W Davidson; Chyke A Doubeni; John W Epling; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; Maureen G Phipps; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng
Journal:  JAMA       Date:  2018-02-13       Impact factor: 56.272

8.  No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.

Authors:  Shannon Salvador; Stephanie Scott; Julie Ann Francis; Anita Agrawal; Christopher Giede
Journal:  J Obstet Gynaecol Can       Date:  2017-06

9.  Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Mary B Daly; Tuya Pal; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Michael Goggins; Mollie L Hutton; Beth Y Karlan; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Holly J Pederson; Gwen Reiser; Leigha Senter-Jamieson; Kristen Mahoney Shannon; Rebecca Shatsky; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Matthew B Yurgelun; Susan D Darlow; Mary A Dwyer
Journal:  J Natl Compr Canc Netw       Date:  2021-01-06       Impact factor: 11.908

10.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335

View more
  2 in total

1.  Racial and ethnic differences in the adoption of opportunistic salpingectomy for ovarian cancer prevention in the United States.

Authors:  Pritesh S Karia; Yongmei Huang; Parisa Tehranifar; Kala Visvanathan; Jason D Wright; Jeanine M Genkinger
Journal:  Am J Obstet Gynecol       Date:  2022-04-27       Impact factor: 10.693

2.  Possible Association of Hysterectomy Accompanied with Opportunistic Salpingectomy with Early Menopause: A Retrospective Cohort Study.

Authors:  Pei-Chen Chen; Pei-Chen Li; Dah-Ching Ding
Journal:  Int J Environ Res Public Health       Date:  2022-09-20       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.